Table 2.
Baseline clinical characteristics by index therapy cohort
|
Tiotropium (N = 1561) |
Fluticasone/salmeterol (N = 2976) |
P-value | |||
|---|---|---|---|---|---|
| N | % | N | % | ||
| Respiratory complication | |||||
| Present during baseline | 202 | 12.9 | 380 | 12.8 | 0.870 |
| Comorbid conditions | |||||
| Hypertension | 688 | 44.1 | 1277 | 42.9 | 0.452 |
| Heart disease | 703 | 45.0 | 1223 | 41.1 | 0.011 |
| Disorders of lipid metabolism | 613 | 39.3 | 1114 | 37.4 | 0.226 |
| Respiratory infections | 588 | 37.7 | 1238 | 41.6 | 0.010 |
| Use of breathing agents | |||||
| Use of short-acting beta-agonist | 576 | 36.9 | 967 | 32.5 | 0.003 |
| Use of corticosteroid | 303 | 19.4 | 509 | 17.1 | 0.054 |
| Use of oxygen | 267 | 17.1 | 377 | 12.7 | <0.001 |
| Charlson Comorbidity Index score | |||||
| 0 | 179 | 11.5 | 572 | 19.2 | <0.001 |
| 1 | 793 | 50.8 | 1397 | 47.0 | 0.013 |
| 2 | 298 | 19.1 | 510 | 17.1 | 0.102 |
| 3 | 148 | 9.5 | 275 | 9.2 | 0.791 |
| 4 | 78 | 5.0 | 104 | 3.5 | 0.014 |
| ≥ 5 | 65 | 4.1 | 118 | 4.0 | 0.746 |